line

Press releases 2007

  • 12/17/2007
    Progress in development of Biofronteras BF-1 project for migraine prophylaxis

  • 10/18/2007
    Ad-hoc: Ad-hoc Release pursuant to Section 15 of the German Securities Trading Act (Wertpapierhandelsgesetz)

  • 9/20/2007
    Ad-hoc: Ad-hoc Release pursuant to Section 15 of the German Securities Trading Act (Wertpapierhandelsgesetz)

  • 9/17/2007
    First patient enrolled in third part of Biofrontera's phase II clinical trial with BF-derm1

  • 9/13/2007
    Biofrontera AG elects new chairman of the supervisory board (German only)

  • 8/24/2007
    Biofrontera AG reports first half financial results for 2007

  • 7/10/2007
    Clinical study confirms excellent efficacy of BF-200 ALA in actinic keratosis

  • 5/3/2007
    First patient enrolled in phase II study of BF-37 in atopic dermatitis

  • 4/30/2007
    Ad-hoc: Ad-hoc Release pursuant to Section 15 of the German Securities Trading Act

  • 4/13/2007
    Biofrontera reports financial results for fiscal year 2006 (German only)

  • 3/2/2007
    Ad-hoc: Ad-hoc Release pursuant to Section 15 of the German Securities Trading Act

  • 2/26/2007
    Biofrontera has successfully completed a first human trial with its migraine prophylaxis compound BF-1

  • 1/16/2007
    Ad-hoc: Ad-hoc Release pursuant to Section 15 of the German Securities Trading Act

line2